Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Shuji Ogino, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Shuji Ogino and Kimmie Ng.
Connection Strength

5.533
  1. Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. Cancer Immunol Immunother. 2022 Apr; 71(4):933-942.
    View in: PubMed
    Score: 0.240
  2. Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis. Cancers (Basel). 2021 Apr 22; 13(9).
    View in: PubMed
    Score: 0.233
  3. Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. Clin Cancer Res. 2021 05 15; 27(10):2816-2826.
    View in: PubMed
    Score: 0.231
  4. Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):757-764.
    View in: PubMed
    Score: 0.230
  5. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021 04; 18(4):230-243.
    View in: PubMed
    Score: 0.226
  6. Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2323-2331.
    View in: PubMed
    Score: 0.223
  7. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer. 2020 09; 123(5):844-851.
    View in: PubMed
    Score: 0.220
  8. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 04; 111:82-93.
    View in: PubMed
    Score: 0.201
  9. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
    View in: PubMed
    Score: 0.200
  10. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer. 2018 11; 103:98-107.
    View in: PubMed
    Score: 0.195
  11. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr. 2016 05; 115(9):1643-60.
    View in: PubMed
    Score: 0.165
  12. Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer. 2016 04 26; 114(9):995-1002.
    View in: PubMed
    Score: 0.164
  13. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2016 Feb; 65(2):296-304.
    View in: PubMed
    Score: 0.151
  14. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
    View in: PubMed
    Score: 0.150
  15. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
    View in: PubMed
    Score: 0.139
  16. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with ß-catenin (CTNNB1) status. Cancer Res. 2013 Mar 01; 73(5):1600-10.
    View in: PubMed
    Score: 0.133
  17. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
    View in: PubMed
    Score: 0.122
  18. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
    View in: PubMed
    Score: 0.119
  19. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev. 2010 Mar; 19(3):822-31.
    View in: PubMed
    Score: 0.108
  20. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2765-72.
    View in: PubMed
    Score: 0.105
  21. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021 09 02; 184(18):4734-4752.e20.
    View in: PubMed
    Score: 0.060
  22. Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. Br J Cancer. 2021 09; 125(7):1016-1024.
    View in: PubMed
    Score: 0.059
  23. Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors. Gastroenterology. 2021 10; 161(4):1208-1217.e9.
    View in: PubMed
    Score: 0.059
  24. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut. 2021 12; 70(12):2330-2336.
    View in: PubMed
    Score: 0.058
  25. Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors. Gastroenterology. 2021 07; 161(1):128-142.e20.
    View in: PubMed
    Score: 0.058
  26. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021 03 01; 7(3):428-435.
    View in: PubMed
    Score: 0.058
  27. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
    View in: PubMed
    Score: 0.055
  28. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1868-1875.
    View in: PubMed
    Score: 0.052
  29. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 08; 7(8):1230-1236.
    View in: PubMed
    Score: 0.051
  30. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
    View in: PubMed
    Score: 0.050
  31. Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. Cancer Prev Res (Phila). 2019 05; 12(5):283-294.
    View in: PubMed
    Score: 0.050
  32. Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. JNCI Cancer Spectr. 2018 Nov; 2(4):pky073.
    View in: PubMed
    Score: 0.050
  33. Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women. JAMA Oncol. 2019 01 01; 5(1):37-44.
    View in: PubMed
    Score: 0.050
  34. Calcium Intake and Survival after Colorectal Cancer Diagnosis. Clin Cancer Res. 2019 03 15; 25(6):1980-1988.
    View in: PubMed
    Score: 0.049
  35. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
    View in: PubMed
    Score: 0.048
  36. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol. 2018 06 01; 4(6):783-790.
    View in: PubMed
    Score: 0.048
  37. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017.
    View in: PubMed
    Score: 0.048
  38. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
    View in: PubMed
    Score: 0.047
  39. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
    View in: PubMed
    Score: 0.047
  40. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.
    View in: PubMed
    Score: 0.047
  41. Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.
    View in: PubMed
    Score: 0.047
  42. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018 04; 154(5):1380-1390.e5.
    View in: PubMed
    Score: 0.046
  43. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448.
    View in: PubMed
    Score: 0.046
  44. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.
    View in: PubMed
    Score: 0.046
  45. Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. Int J Cancer. 2017 12 15; 141(12):2471-2479.
    View in: PubMed
    Score: 0.045
  46. Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut. 2018 08; 67(8):1475-1483.
    View in: PubMed
    Score: 0.045
  47. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017 Jun 01; 35(16):1822-1828.
    View in: PubMed
    Score: 0.044
  48. Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. Int J Cancer. 2017 06 15; 140(12):2648-2656.
    View in: PubMed
    Score: 0.044
  49. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res. 2016 12 15; 76(24):7160-7167.
    View in: PubMed
    Score: 0.043
  50. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut. 2017 06; 66(6):1116-1122.
    View in: PubMed
    Score: 0.043
  51. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206.
    View in: PubMed
    Score: 0.043
  52. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 08 20; 34(24):2899-905.
    View in: PubMed
    Score: 0.042
  53. Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. Cancer Prev Res (Phila). 2016 Aug; 9(8):664-72.
    View in: PubMed
    Score: 0.042
  54. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 Apr 26; 15(4):857-865.
    View in: PubMed
    Score: 0.041
  55. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv409.
    View in: PubMed
    Score: 0.040
  56. Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prev Res (Phila). 2015 Dec; 8(12):1138-45.
    View in: PubMed
    Score: 0.040
  57. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis. 2015 Sep; 36(9):999-1007.
    View in: PubMed
    Score: 0.039
  58. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. Gastroenterology. 2015 Sep; 149(3):614-22.
    View in: PubMed
    Score: 0.039
  59. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
    View in: PubMed
    Score: 0.037
  60. Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1628-37.
    View in: PubMed
    Score: 0.036
  61. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013 Nov 20; 31(33):4229-34.
    View in: PubMed
    Score: 0.035
  62. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011 Nov; 4(11):1808-15.
    View in: PubMed
    Score: 0.029
  63. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.